100 related articles for article (PubMed ID: 22042041)
1. Dose-creep of Infliximab during psoriasis treatment: an observational study.
Mehren CR; Gniadecki R
Acta Derm Venereol; 2012 Jul; 92(4):355-7. PubMed ID: 22042041
[No Abstract] [Full Text] [Related]
2. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients.
Esmailzadeh A; Yousefi P; Farhi D; Bachmeyer C; Cosnes J; Berenbaum F; Duriez P; Aractingi S; Khosrotehrani K
Dermatology; 2009; 219(3):263-7. PubMed ID: 19684381
[TBL] [Abstract][Full Text] [Related]
3. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors.
Meyer MW; Zachariae C; Bendtzen K; Skov L
Acta Derm Venereol; 2012 Jul; 92(4):362-4. PubMed ID: 22864558
[No Abstract] [Full Text] [Related]
4. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
Winterfield L; Menter A
Dermatol Clin; 2004 Oct; 22(4):437-47, ix. PubMed ID: 15450339
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab: a new alternative biologic agent for chronic plaque psoriasis.
Ormerod AD
Br J Dermatol; 2008 Mar; 158(3):435-6. PubMed ID: 18275521
[No Abstract] [Full Text] [Related]
6. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
7. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
Kalb RE; Gurske J
J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
[TBL] [Abstract][Full Text] [Related]
8. The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study.
Saraceno R; Specchio F; Torres T; Nisticò SP; Rizza S; Chimenti S
J Am Acad Dermatol; 2012 May; 66(5):e180-2. PubMed ID: 22507590
[No Abstract] [Full Text] [Related]
9. Therapeutic hotline: Re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: a retrospective analysis.
Vena G; Loconsole F; Mastrandrea V; Buquicchio R; Cassano N
Dermatol Ther; 2010; 23(2):199-202. PubMed ID: 20415828
[TBL] [Abstract][Full Text] [Related]
10. Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study.
Piaserico S; Gisondi P; De Simone C; Marinello E; Conti A; Amerio P; Peserico A
Acta Derm Venereol; 2016 Feb; 96(2):251-2. PubMed ID: 26270599
[No Abstract] [Full Text] [Related]
11. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
Kamili QU; Miner A; Hapa A; Menter A
J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
[TBL] [Abstract][Full Text] [Related]
12. [Infliximab].
Herrera E; Habicheyn S
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
DE Oliveira JP; Levy A; Morel P; Guibal F
J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
[TBL] [Abstract][Full Text] [Related]
15. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
Chaparro M; Panes J; García V; Mañosa M; Esteve M; Merino O; Andreu M; Gutierrez A; Gomollón F; Cabriada JL; Montoro MA; Mendoza JL; Nos P; Gisbert JP
J Clin Gastroenterol; 2011 Feb; 45(2):113-8. PubMed ID: 21242747
[TBL] [Abstract][Full Text] [Related]
16. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis.
Wu JJ; Tsai TF
Arch Dermatol; 2008 Oct; 144(10):1403-4. PubMed ID: 18936418
[No Abstract] [Full Text] [Related]
17. "Paradoxical" adverse effects caused by anti-tumor necrosis factor-α biological drugs: appearance of psoriasis in a patient treated with infliximab for rheumatoid arthritis.
Satriano RA; Abbate G; Esposito S; Cassaglia B; Piccolo V; Baroni A
Indian J Dermatol Venereol Leprol; 2011; 77(4):536. PubMed ID: 21727719
[No Abstract] [Full Text] [Related]
18. Sustained effects of low dose infliximab in combination with methotrexate in the management of chronic recalcitrant psoriasis.
Zargari O
Dermatol Online J; 2005 Dec; 11(3):21. PubMed ID: 16409917
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy and safety of infliximab in patients with ankylosing spondylitis: results of an open-labeled multicenter study].
Bunchuk NV; Rumiantseva OA; Loginova EIu; Bochkova AG; Storozhakov GI; Ettinger OA; Kosiura SD; Kamalova RG; Valishina LM
Ter Arkh; 2010; 82(10):41-6. PubMed ID: 21341463
[TBL] [Abstract][Full Text] [Related]
20. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.
Gisondi P; Cazzaniga S; Chimenti S; Giannetti A; Maccarone M; Picardo M; Girolomoni G; Naldi L;
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e30-41. PubMed ID: 22313340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
